UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000023854
Receipt No. R000027465
Scientific Title Efficacy Study of Repeated Doses of L-arginine in Patients with HTLV-1 Associated Myelopathy
Date of disclosure of the study information 2016/08/31
Last modified on 2020/03/13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Efficacy Study of Repeated Doses of L-arginine in Patients with HTLV-1 Associated Myelopathy
Acronym Efficacy Study of Repeated Doses of L-arginine in Patients with HTLV-1 Associated Myelopathy
Scientific Title Efficacy Study of Repeated Doses of L-arginine in Patients with HTLV-1 Associated Myelopathy
Scientific Title:Acronym Efficacy Study of Repeated Doses of L-arginine in Patients with HTLV-1 Associated Myelopathy
Region
Japan

Condition
Condition HTLV-1-Associated-Myelopathy Tropical Spastic Paraparesis (HAM/TSP)
Classification by specialty
Neurology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the safety and efficacy of L-arginine in patients with HTLV-1 associated myelopathy
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes - Efficacy:
Change in walking speed as measured by 10 meter walk test from Day 0 to Day 7 (time and number of steps)
Key secondary outcomes - Efficacy:
Change in walking speed as measured by 10 meter walk test from Day 0 to Day 3 and 14 (time and number of steps)
Change in measurements obtained with timed up and go test from Day 0 to Day 3, 7 and 14 (time and number of steps)
Degree of improvement in cell count, protein level and neopterin concentration in spinal fluid

- Safety:
Adverse event (frequency and severity)

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification NO
Dynamic allocation NO
Institution consideration Institution is not considered as adjustment factor.
Blocking NO
Concealment No need to know

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Patients take 0.5g/kg of Argi-U Granule 2-4 times a day for 7 days.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria (1) Patients diagnosed with HAM/TSP
(2) Patients must have signed an informed consent form at age 20 or older
(3) In patients receiving steroid therapy, a prednisolone-equivalent daily dose of 10 mg or less must be continuously administered for 12 weeks or more without dose modification
(4) Patients who are able to walk at least 10 meters with or without the use of walking aids at the time of signing the patient informed consent
(5) Patients must have voluntarily signed written informed consent to participate in the study
(6) Patients who can and plan to visit the hospital according to the study schedule
Key exclusion criteria (1) Patients for whom dosage or mode of administration of steroids or other drugs targeting HAM/TSP has been changed within 12 weeks prior to signing the patient informed consent
(2) Patients who have received pulse steroid therapies or doses of interferon within one year prior to signing the patient informed consent
(3) Patients who have participated in interventional studies within 16 weeks prior to signing the patient informed consent
(4) Patients whose result of 10 meters walk test obtained on screening varies by more than 30 percent compared to those obtained within eight weeks prior to signing the patient informed consent, which include any data collected during single or multiple hospital visits
(5) Patients with serious complications such as heart failure, lung diseases, kidney failure, liver failure and uncontrolled diabetes
(6) Patients with cancer or history of cancer
Note, however, that patients with solid tumors which were completely removed and have not recurred within three years prior to signing the patient informed consent may be included. Patients with basal cell cancer of skin, squamous cell cancer (except for malignant melanomas), non-invasive cervical cancer, or cancer in situ of the gastrointestinal tract or corpus uteri, which have been completely cured may also be included even if the patient developed one of those diseases within three years prior to signing the patient informed consent
(7) Patients with ATL
(8) Pregnant or breast-feeding women, women suspected of being pregnant and patients who do not consent to prevent conception by taking appropriate means with the assistance of their partners during the study period
(9) Patients with compressive spinal cord lesions such as osteoarthritis of the spine, ossification of posterior longitudinal ligament, ossification of yellow ligament, which preclude assessment using the walk tests or can worsen the patients symptoms
Target sample size 20

Research contact person
Name of lead principal investigator
1st name Hiroshi
Middle name
Last name Takashima
Organization Kagoshima University Hospital
Division name Department of Neurology
Zip code 890-8520
Address 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima 890-8520, Japan
TEL 099-275-5332
Email thiroshi@m3.kufm.kagoshima-u.ac.jp

Public contact
Name of contact person
1st name Eiji
Middle name
Last name Matsuura
Organization Kagoshima University Hospital
Division name Department of Neurology
Zip code 890-8520
Address 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima 890-8520, Japan
TEL 099-275-5332
Homepage URL
Email pine@m.kufm.kagoshima-u.ac.jp

Sponsor
Institute Kagoshima University Hospital
Institute
Department

Funding Source
Organization The Research on Measures for Intractable Diseases Project of Japan Agency for Medical Research and Development
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Kagoshima University Clinical Research Review Board
Address 1-21-24 Korimoto, Kagoshima
Tel 099-275-6624
Email crmc@m2.kufm.kagoshima-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 鹿児島大学病院(鹿児島県)

Other administrative information
Date of disclosure of the study information
2016 Year 08 Month 31 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2016 Year 08 Month 05 Day
Date of IRB
2019 Year 05 Month 29 Day
Anticipated trial start date
2016 Year 10 Month 17 Day
Last follow-up date
2017 Year 04 Month 01 Day
Date of closure to data entry
2021 Year 04 Month 30 Day
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2016 Year 08 Month 31 Day
Last modified on
2020 Year 03 Month 13 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027465

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.